|
The Michael J. Fox Foundation for Parkinson's Research is dedicated to finding a cure for Parkinson's disease (PD) through an aggressively funded research agenda and to ensure the development of improved therapies for those living with Parkinson's today. Established by actor Michael J. Fox in 2000, the Foundation has since become the largest nonprofit funder of Parkinson's disease research in the world, investing more than $450 million in research to date.〔(The Michael J. Fox Foundation for Parkinson's Research )〕 The Foundation's proactive approach to advancing PD science has made it "the most credible voice on Parkinson's research in the world".〔(Taking Science Personally )〕 In 2010 the Fox foundation launched the first large scale clinical study on evolution biomarkers of the disease at a cost of $45 million dollars over 5 years. ==Research funding== The Foundation targets people's high-risk, "translational" research—the work of translating basic scientific discoveries into simple treatments with definition to benefit the estimated five million people living with Parkinson's disease today.〔(Our Research: The Michael J. Fox Foundation )〕 The Foundation drives progress by awarding grants to ensure that the most promising research avenues are thoroughly funded, explored and carried forward toward pharmacy shelves.〔(Funding Opportunities: The Michael J. Fox Foundation )〕 The Foundation's four annually recurring ''Pipeline Programs'' aim to speed research along the drug development pipeline.〔(Pipeline Programs: The Michael J. Fox Foundation )〕 The ''Pipeline Programs'' include: ''Rapid Response Innovation Awards'' quickly support high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD (an Edmond J. Safra Core Program for PD Research). ''Target Validation Awards'' provide support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model — an essential step to the development of potential targeted therapies (an Edmond J. Safra Core Program for PD Research). ''Clinical Intervention Awards'' support clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD (an Edmond J. Safra Core Program for PD Research). ''Therapeutics Development Initiative'', an industry-exclusive support program for preclinical development of Parkinson’s disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care. The ''Pipeline Programs'' are complemented by the Foundation's ''Critical Challenges in Parkinson's Disease'' program, which provides funds for top research priorities.〔(Critical Challenges: The Michael J. Fox Foundation )〕 ''Critical Challenges'' in 2009/2010 include: speeding research on PD genetic targets, LRRK2 and alpha-synuclein; advancing research on neurotrophic factors; identifying biomarkers of PD; understanding patient's unmet needs, like postural instability and gait disturbances; and, promoting collaborations with the Arizona Parkinson's Disease Consortium. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「The Michael J. Fox Foundation」の詳細全文を読む スポンサード リンク
|